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Abstract
Background: In the setting of primary percutaneous coronary intervention, patients with a chronic total occlusion
in a non-infarct related artery were recently identified as a high-risk subgroup. It is unclear whether ST-elevation
myocardial infarction patients with a chronic total occlusion in a non-infarct related artery should undergo
additional percutaneous coronary intervention of the chronic total occlusion on top of optimal medical therapy
shortly after primary percutaneous coronary intervention. Possible beneficial effects include reduction in adverse
left ventricular remodeling and preservation of global left ventricular function and improved clinical outcome
during future coronary events.
Methods/Design: The Evaluating Xience V and left ventricular function in Percutaneous coronary intervention on
occLusiOns afteR ST-Elevation myocardial infarction (EXPLORE) trial is a randomized, prospective, multicenter, two-
arm trial with blinded evaluation of endpoints. Three hundred patients after primary percutaneous coronary
intervention for ST-elevation myocardial infarction with a chronic total occlusion in a non-infarct related artery are
randomized to either elective percutaneous coronary intervention of the chronic total occlusion within seven days
or standard medical treatment. When assigned to the invasive arm, an everolimus-eluting coronary stent is used.
Primary endpoints are left ventricular ejection fraction and left ventricular end-diastolic volume assessed by cardiac
Magnetic Resonance Imaging at four months. Clinical follow-up will continue until five years.
Discussion: The ongoing EXPLORE trial is the first randomized clinical trial powered to investigate whether
recanalization of a chronic total occlusion in a non-infarct related artery after primary percutaneous coronary
intervention for ST-elevation myocardial infarction results in a better preserved residual left ventricular ejection
fraction, reduced end-diastolic volume and enhanced clinical outcome.
Trial registration: trialregister.nl NTR1108.
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Treatment of patients with acute ST-elevation myocar-
dial infarction (STEMI) aims at early restoration of ante-
grade flow in the infarct related coronary artery in order
to preserve myocardial function and improve survival.
Angiography after thrombolysis or before primary percu-
taneous coronary intervention (PCI) has revealed that
multivessel disease (MVD) is present in 40-65% of all
STEMI patients. These patients are considered to be a
subgroup with a high risk for morbidity and mortality,
compared with patients with single vessel disease (SVD).
[1,2] An aggressive multivessel PCI strategy during and
after primary PCI for STEMI has not improved outcome
in MVD patients. In fact, studies reported that treatment
of non-culprit lesions in STEMI patients with MVD is
associated with a higher post-procedural morbidity rate
without improving survival.[3-5] In the setting of primary
PCI it was recently demonstrated that, the higher mortal-
ity in patients with MVD is mainly determined by the
presence of a chronic total occlusion (CTO) in a non-
infarct related artery (IRA).[6-10] Furthermore, a CTO in
a non-IRA was associated with a reduced left ventricular
function during hospitalization for the index event and a
further reduction in left ventricular function during
follow-up.[6] Therefore, STEMI patients with a CTO
constitute the MVD patient group with a truly higher
risk for death.[6-9] The ongoing Evaluating Xience V and
left ventricular function in PCI on occLusiOns afteR
STEMI (EXPLORE) trial is the first randomized clinical
trial powered to investigate clinical outcome after percu-
taneous treatment of a CTO. There are two main
mechanisms involved in the hypothesis of the Explore
trial. First, recanalization of the CTO will possibly restore
the contractile function of the hibernating myocardium.
Furthermore, recanalization of the CTO might improve
the healing of the infarct border zone. This assumption is
based on the coronary anatomy where the perfusion area
of the infarct related coronary artery and the CTO are
adjacent or overlapping. In recently perfused myocar-
dium, the revascularization of a CTO will improve the
myocardial perfusion in this overlapping region and
therefore might improve the healing of this border zone
and might protect against negative remodelling and pre-
serving residual left ventricular function.
The EXPLORE trial will determine whether recanali-
zation of a CTO within one week after primary PCI for
STEMI results in a better preserved residual left ventri-
cular ejection fraction and reduced end-diastolic volume.
Methods/Design
Overview
The investigator-initiated EXPLORE trial is a prospec-
tive, randomized, two-arm trial with blinded evaluation
of endpoints. European and North-American high
volume primary PCI centers with a 1.5 Tesla cardiovas-
cular magnetic resonance imaging (cMRI) facility parti-
cipate in this global trial. The study was first approved
by the Medical Ethics Committee on human research at
the Academic Medical Center-University of Amsterdam,
the Netherlands. For all the foreign centers, the study
must be approved by the Medical Ethics Committee on
human research in each of the corresponding countries
before participation. The study will be conducted in
accordance with the declaration of Helsinki. The
EXPLORE trial was registered on 30-10-2007 at http://
www.trialregister.nl with trial ID NTR1108.[11]
After successful primary PCI for STEMI, patients with
a CTO in a non-infarct related artery are randomized to
either elective PCI of the CTO within seven days after
primary PCI or to standard medical treatment. Figure 1
shows the flow chart of the trial.
Patients and Enrolment
Consecutive STEMI patients after successful primary
PCI, defined as a residual stenosis of the culprit lesion <
30% and a TIMI flow ≥ 2, are screened for entry into
the EXPLORE trial. Patients are suitable for inclusion if
coronary angiography preceding the primary PCI reveals
at least one CTO, situated in a non-infarct related cor-
onary artery or its side branches. For the purpose of this
trial, a CTO is defined as a 100% luminal narrowing
without antegrade flow or with antegrade or retrograde
filling through collateral vessels. Furthermore, the CTO
should be amenable to percutaneous treatment and
must be located in a coronary vessel with a reference
diameter of at least 2.5 millimeters. All inclusion and
exclusion criteria are summarized in Appendix A and B,
respectively.
If all inclusion and none of the exclusion criteria are
met, the patient is asked for written informed consent,
as required by the institutional review board in accor-
dance with the Declaration of Helsinki.
Randomized Treatment Assignment
After informed consent has been obtained, the local
investigator contacts the EXPLORE website http://www.
explorerandomization.org for online randomization.
Patients are randomly assigned following a computer-
generated list in a 1:1 ratio to either PCI of the CTO
within seven days after the primary PCI or to standard
medical treatment.
PCI of the CTO(s)
All PCI procedures are performed under the local rou-
tine protocols. All angiograms are recorded in such a
way that they are suitable for off-line quantitative
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to PCI of the CTO, the procedure is planned as soon as
possible after randomization, but at the latest within
seven days after the primary PCI. An approved drug
eluting stent is used during PCI of the CTO. For the
purpose of uniformity in this trial, the investigators
intend to use an everolimus eluting stent (EES) in order
to study the performance of the EES in this type of
lesion with a high risk of restenosis. Routine electrocar-
diography and blood analysis including cardiac enzymes
are performed before and after PCI of the CTO and are
repeated at discharge. Patients randomized to this treat-
ment arm receive clopidogrel 75 mg daily or prasugrel
10 mg daily for at least 12 months after drug eluting
stent placement [12,13].
Standard Medical Treatment
In patients randomized to standard medical treatment,
the non-infarct related CTO should not be approached
invasively during the first four months after randomiza-
tion. If, however an unequivocal indication for revascu-
larization arises, follow-up cMRI should be performed
before CTO intervention.
Post-STEMI Treatment for Patients with non CTO co-
existing coronary lesions
In view of the weak guideline recommendations [14]
and the different local practices, our protocol recom-
mends a conservative approach for non-CTO co-existing
lesions in the EXPLORE trial. In order to assess the
value of CTO revascularization but in view of current
Figure 1 Flow chart of the EXPLORE trial. STEMI = ST elevation myocardial infarction PCI = Percutaneous Coronary Intervention CTO =
Chronic Total Occlusion
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of non-CTO co-existing lesions must be made before
randomization. This decision is made by the local heart
team, which generally consist of an interventional cardi-
ologist and or a cardio-thoracic surgeon. In case it
is decided that a non-CTO co-existing lesion should
be treated, this additional PCI procedure must be
performed within one week after the index STEMI.
For patients randomized to recanalize the CTO, this
additional PCI procedure will be performed during the
same procedure as the CTO lesion is being treated. For
patients in the conservative group, this additional PCI
for non-CTO co-existing lesions will be scheduled
within one week after the index STEMI. After the first
week, revascularization is only indicated when clinically
and or ischemia driven and is preferably performed after
four months.
Post-STEMI Treatment for all Patients
All patients included in this trial are treated according
to the current ACC/AHA guidelines regarding post
STEMI management specifying treatment with at least
100 mg of aspirin daily, clopidogrel in a dosage of at
least 75 mg daily or prasugrel 10 mg daily for at least 12
month after primary PCI, adequate lipid-lowering medi-
cation, angiotensin converting enzyme (ACE) inhibitors,
and beta-blockers.[12,13]
Follow-up
All patients visit the outpatient clinic at 30 days, four
months, and twelve months after primary PCI. There-
after, patients will be followed-up by means of a tele-
phone call at two, three, four, and five years. During all
three follow-up outpatient clinic visits, clinical evalua-
tion with a 12-lead electrocardiogram and an inventory
of adverse events is obtained. Adverse events included
in this inventory are cardiac and non-cardiac death,
stent thrombosis according to the definition of the Aca-
demic Research Consortium (ARC)[15] myocardial re-
infarction, all cardiac surgery, implantation of an
implantable cardioverter-defibrillator device, clinically
overt heart failure, repeat coronary angiography and
repeat PCI, hospital admission for angina, stroke, and
severe bleeding events.
At four months, cMRI is performed in all patients
along with routine laboratory measurements and exercise
testing. If a contraindication for cMRI has risen because
of altered patient characteristics after inclusion, the pro-
tocol permits single positron emission computed tomo-
graphy (SPECT) as a secondary and echocardiography as
a tertiary modality for endpoint assessment.
Scheduling of repeat angiography is at the discretion of
the treating physician. Repeat angiography is preferably
performed at one year after randomization in all patients.
Cardiac Magnetic Resonance Imaging
After written informed consent, baseline cMRI is recom-
mended to be performed at least 48 hours after the
primary PCI but before the patient is randomly assigned
to one of the treatment arms. All patients undergo
cMRI at four-month follow-up to assess the primary
endpoints of this trial. Patients are studied on a clinical
1.5-Tesla scanner using a 4-element phased array car-
diac receiver coil. For functional imaging, electrocardio-
gram-gated cine steady-state, free-precession magnetic
resonance images are obtained during repeated breath
holds in the 3 standard long-axis views (4 -, 3- and
2-chamber view). Additional short-axis slices are
acquired, covering the entire left ventricle from base to
apex, to examine regional and global left ventricular
function. Late contrast-enhanced (LCE) images are
acquired 10 minutes after administration of a gadoli-
nium-based contrast agent with an inversion recovery,
gradient-echo pulse sequence to identify the location
and extent of myocardial infarction. The data are
obtained with slice locations identical to the functional
images. All MRI images are sent to an independent core
laboratory for quality control and blinded central analy-
sis. On the short axis cine slices, the endocardial and
epicardial borders are outlined manually in end-diastolic
and end-systolic images, excluding trabeculae and papil-
lary muscles. Assessment of global left ventricular func-
tion is obtained by calculating left ventricular volumes,
mass, and ejection fraction using the summation of slice
method multiplied by slice distance.
Primary Endpoints
The two primary endpoints of this trial are differences
between the two treatment arms in left ventricular ejec-
tion fraction (LVEF) and left ventricular end-diastolic
volume (LVEDV), assessed by cMRI at four months
after primary PCI for STEMI, Appendix C.
Safety and Other Secondary Endpoints
Safety will be determined by the assessment of Major
Adverse Coronary Events (MACE) defined as cardiac
death, peri-procedural myocardial infarction, myocardial
infarction or any repeat coronary intervention at 30
d a y s ,4m o n t h sa n d1 ,2 ,3 ,4 ,5y e a r s .F u r t h e r m o r e ,
safety is also determined b yt h eo c c u r r e n c eo fs t e n t
thrombosis. All safety endpoints are defined in accor-
dance with the ARC [15]. The trial will be monitored by
a Data and Safety Monitoring Board (DSMB) and the
trial will be discontinued in case of safety concerns.
All other secondary endpoints are displayed in
Appendix C.
A pre-specified subgroup analysis will be performed in
which the primary outcome, Major Adverse Coronary
Events (MACE) and suitable other secondary endpoints
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co-existing lesions.
Statistical Considerations
Both primary and all secondary endpoints are displayed
in Appendix C.
As this study has two primary endpoints, the Hoch-
berg extension of the Bonferroni method for multiple
comparisons will be used to test for statistical signifi-
cance with an overall type I error rate less than or equal
to 0.05 [16]. The statistical comparisons of the treat-
ment arms with respect to the primary and secondary
endpoints are performed using the independent-samples
T-test, or Fisher’s exact probability test in case of binary
endpoints. All p-values are 2-sided. For clinical out-
comes such as the incidence of major adverse cardiac
events, Kaplan-Meier curves displaying the pattern of
events over the four-month and one-year follow-up per-
iod are constructed. Statistical significance and 95-%
confidence intervals are calculated using Cox’ propor-
tional hazards model.
The trial is powered to detect differences between the
t w og r o u p si nc M R Ia s s e s s e dL V E Fa n dL V E D Va tf o u r
months after STEMI. With 2 × 150 randomized patients,
this trial has an 80% power to detect absolute differences
of 4% in LVEF and 15 mL in LVEDV in favor of PCI of
the CTO with a one-sided alpha of 5%. For this calcula-
tion we have assumed that PCI of a CTO is successful in
80% of cases. The mean global ejection fraction in
patients with an untreated CTO is assumed to be 36%
against 40% in patients with successful CTO treatment
with a common standard deviation of 12%. Consequently,
the expected global ejection fraction is 40% (0.8 × 41% +
0.2 × 36%) in patients randomized to CTO treatment
against 36% in patients randomized to standard medical
treatment. The calculation for the second primary end-
point is based on the assumption of a net mean LVEDV
of 185 ml for patients randomized to CTO treatment and
of 200 ml for patients randomized to standard medical
treatment. The standard deviation for LVEDV was
assumed to be 45 ml. Patients who have deceased before
primary endpoint measurement will be attributed the
lowest LVEF and the largest LVEDV measured in the
whole study cohort. The primary endpoint will be
analyzed on an intention-to-treat basis.
Study Organization and Monitoring
An executive committee will supervise the EXPLORE
trial, while a study coordination committee will coordi-
nate the trial and perform QCA analysis. The steering
committee is responsible for design and conduct of the
study. An independent data and safety monitoring board
watches over the ethics of conducting the study in
accordance with the Declaration of Helsinki, monitors
the patient safety, and reviews safety issues as the study
progresses. All major adverse cardiac events will be
adjudicated by a Critical Events Committee. The specific
role and information regarding each of the committees
appear in appendix D.
Discussion
Prognosis after primary PCI
After primary PCI for acute STEMI, patients with MVD
have a worse clinical outcome when compared to
patients with SVD.[1,2,6,17] Previous randomized stu-
dies investigating multivessel PCI during the primary
procedure or shortly thereafter have been hampered by
small patient numbers and have failed to show clinical
benefit of additional revascularization after primary PCI.
[18,19] Furthermore, a number of observational studies
investigating the value of additional revascularization
after primary PCI have reported inconclusive results.
[3-5,20-22]
Recently, we reported that patients with a CTO in a
non-IRA are the subgroup of MVD patients who are
truly at risk after primary PCI for STEMI.[6,8] A CTO in
a non-IRA was a strong and independent predictor of
30-day, 1-year, and 5-year mortality whereas MVD with-
out a CTO was only a weak predictor of 30-day mortality,
and not an independent predictor of 1-year, and 5-year
mortality. We reported similar results in a cohort consist-
ing exclusively of STEMI patients with cardiogenic shock.
[9] Furthermore, a CTO in a non-IRA was associated
with reduced LVEF during the index hospitalization and
a further reduction in LVEF within the first year there-
after.[6] Therefore, rather than a significant diseased con-
comitant coronary artery, a CTO in a non-IRA is a target
for additional revascularization after primary PCI.
T h e s ef i n d i n g sd r i v et h er a t i o n a l eb e h i n dt h e
EXPLORE trial. Recanalization of a CTO in a non-IRA
shortly after primary PCI may improve regional myocar-
dial function and promote infarct healing at the border
zones. These effects may attenuate the remodeling pro-
cess, which may lead to a better preserved residual glo-
bal LV function, decreased LVEDV, and improved
survival. This trial will be the first to prospectively
determine the effect of PCI of a CTO in a non-IRA in
the early recovery phase after successful primary PCI for
STEMI on LV performance.
LV function after elective PCI of a CTO
LVEF and LVEDV are major prognostic determinants in
patients with coronary artery disease. It is suggested that
opening of CTO’s in an elective setting can be of benefit by
restoring blood flow to hibernating myocardium and thus
improving LV function. Improvement of LV function and
a reduction of both end-diastolic and end-systolic volume
after recanalization of a CTO has been demonstrated in
van der Schaaf et al. Trials 2010, 11:89
http://www.trialsjournal.com/content/11/1/89
Page 5 of 9several studies, provided long-term patency could be
achieved.[23-26]
PCI of a CTO: higher risk of restenosis
Percutaneous recanalization of a CTO amenable to PCI
treatment can be performed with a success rate of 70-80%,
but is associated with a higher rate of restenosis compared
to PCI of non-occluded vessels. Although coronary stent-
ing has been shown to be superior to conventional balloon
angioplasty, restenosis rates remain relatively high. When
compared to bare metal stents, drug eluting stents (DES)
are effective in decreasing the need for repeat intervention
in successfully treated CTO patients.[27] However, there
have been concerns about long-term delay of arterial heal-
ing as a consequence of both Sirolimus eluting stent (SES)
and Paclitaxel eluting stent (PES) placement and the asso-
ciated risk of late stent thrombosis. Both preclinical and
clinical data for a second-generation DES, the EES, are
encouraging in terms of arterial healing and low restenosis
rates. The EES showed superior endothelialization com-
pared with the PES, SES and Zotarolimus-eluting stent at
14 days after stent implantation.[28] This suggests a super-
ior safety profile for the EES, as shown in the one-year
results of the SPIRIT IV trial, randomizing 3687 patients in
a 2:1 fashion to either the EES or the PES for treatment of
patients with de novo coronary artery disease with a maxi-
mum of 3 lesions. The SPIRIT IV investigators reported a
0.29% ARC definite or probable stent thrombosis rate in
the EES arm, as compared to 1.1% in the PES arm (p =
0.003). Furthermore, the EES performed superior over the
PES regarding ischemia-driven target lesion revasculariza-
tion, (3.9% vs 6.6%, p = 0.0008).[29] Although extensively
studied in relatively low-risk lesions, currently data regard-
ing the performance of the EES in CTO’s are lacking.
To conclude, no clinical trial to date has investigated
the effect of percutaneous recanalization of CTO’so n
clinical endpoints in any setting. The high case-fatality
rates and inferior recovery of LV function after STEMI
of patients with a CTO in a non-IRA provide the ratio-
nale for the current trial. The ongoing EXPLORE trial is
the first randomized clinical trial powered to investigate
clinical outcome after percutaneous treatment of a
CTO. The Explore trial will determine whether recanali-
zation of a CTO within one week after primary PCI for
STEMI results in a better preserved residual left ventri-
cular ejection fraction and reduced end-diastolic volume.
Appendix A
Inclusion criteria EXPLORE trial
Patients are eligible for inclusion if all of the inclusion
criteria are met:
- Successful primary percutaneous coronary interven-
tion
1 for acute ST elevation myocardial infarction
2
And
- Presence of at least one chronic total occlusion
located in a non-infarct related coronary artery,
defined as a 100% luminal narrowing without ante-
grade flow or with antegrade or retrograde filling
through collateral vessels
And
- Reference diameter of ≥2.5 millimeters
And
- Amenable to treatment by percutaneous coronary
intervention
1 Residual stenosis of the culprit lesion < 30% and
Thrombolysis In Myocardial Infarction flow ≥ 2.
2 definition according to Alpert et al. Myocardial
infarction redefined - a consensus document of The
joint ESC/ACC committee for the redefinition of
myocardial infarction [30].
Appendix B
Exclusion criteria EXPLORE trial
Age > 80 years
Persistent or permanent atrial fibrillation
Known renal insufficiency (serum creatinin > 265
μmol/L or > 3.5 mg/L)
Persistent hemodynamic instability
1 lasting up to 48
hours after primary PCI
Cardiac events
2 between primary PCI and
randomization
Significant left main stenosis (diameter stenosis ≥ 50%)
Severe coronary artery disease, not amenable for PCI
but suitable for coronary artery bypass grafting
Severe valvular heart disease requiring cardiac surgery
within four months
Clinically driven indication for implantable cardiover-
ter defibrillator within four months
Inability to schedule the index procedure within seven
days after primary PCI
Contraindication for cMRI (i.e. pacemaker, cerebrovas-
cular clips, or claustrophobia)
Serious known concomitant disease with a life expec-
tancy of less than one year
Circumstances that prevent follow-up
Previous participation in this trial or any other trial
within the previous 30 days
1 Defined as pre-shock (heart rate > 100/min, and/or
systolic blood pressure < 100 mm Hg) or shock
2 Defined as extended myocardial infarction, acute
stent thrombosis, or late (> 48 hours after primary
PCI) and life threatening ventricular arrythmias
PCI = Percutanous Coronary Intervention, cMRI =
cardiovascular Magnetic Resonance Imaging
van der Schaaf et al. Trials 2010, 11:89
http://www.trialsjournal.com/content/11/1/89
Page 6 of 9Appendix C
EXPLORE trial endpoints
Primary Endpoints
Measured by cardiovascular magnetic resonance imaging
at 4 months:
- Left ventricular ejection fraction
- Left ventricular end-diastolic volume
Secondary Endpoints
Safety Endpoints
Major Adverse Cardiac Events, defined as cardiac death,
myocardial infarction or any repeat coronary
intervention* at 30 days, 4 months, and 1, 2, 3, 4, and
5 years
Stent thrombosis, classified as definite, probable or
possible
Other Secondary Endpoints
Measured by cardiac magnetic resonance imaging at
4 months:
- Left ventricular end-systolic volume - Left ventricu-
lar segmental wall thickening
- Left ventricular mass - Infarct size (by late contrast
enhancement)
N Terminal - pro Brain Natriuretic Peptide (at
4 months and 1 year, relative to baseline)
Heart rate-adjusted QT (QTc) duration measured by
resting electrocardiography (at 4 months and 1 year,
relative to baseline)
Quantitative Coronary Angiography of the treated
chronic total occlusions:
- in-stent and in-segment late luminal loss at 12
months
- in-stent and in-segment minimal luminal diameter
- in-stent and in-segment binary restenosis rate
Repeat Hospitalization for cardiac causes at 30 days,
4 months, and 1, 2, 3, 4, and 5 years
Presence of clinically overt heart failure at 30 days,
4 months, and 1, 2, 3, 4, and 5 years
Implantation of implantable cardioverter-defibrillator
devices
Functional Class: NYHA classification at 30 days,
4 months, and 1, 2, 3, 4, and 5 years
*Excluding the initial percutaneous coronary interven-
tion of the chronic total occlusion when randomly
assigned to this treatment arm. MRI: Magnetic reso-
nance imaging NYHA: New York Heart Association
Appendix D
Executive Committee
The Executive Committee will be composed of the study
principal investigators and selected members among the
investigators. This committee is responsible for overseeing
the administrative progress of the study and approval of
the final trial design and protocol issued to the DSMB and
the clinical sites. This committee will also be responsible
for reviewing the final results, determining the methods of
presentation and publication, and selecting the secondary
projects and publications by members of the Steering
Committee. The executive committee also holds the right
to modify or stop the study prematurely based on recom-
mendations from the DSMB.
Steering Committee
The Steering Committee will be composed of the princi-
pal investigators from the participating centers in this
trial. The Steering Committee is responsible for the day-
to-day administrative management of the trial and will
meet on a monthly basis to monitor subject enrollment,
clinical site progress and protocol compliance. It will be
the responsibility of the Steering Committee to provide
assistance and education to individual sites and
researchers to help with trial management, record keep-
ing, and reporting requirements.
Data Safety Monitoring Board
The Data Safety Monitoring Board (DSMB) will be com-
posed of general and interventional cardiologists and a
biostatistician. The DSMB will function in accordance
with applicable regulatory guidelines. The board mem-
bers are independent and will not be participating in the
trial. The DSMB will review the safety data from this
trial and will make recommendations based on safety
analyses of unanticipated device effects, serious adverse
events, protocol deviation, and device failures. The
DSMB will meet annually; in addition, the DSMB may
meet at any time if there is reason to suspect that safety
is an issue. The DSMB is responsible for making recom-
mendations regarding any safety or compliance issues
throughout the course of the study and may recommend
to the Executive Committee to modify or stop the study.
However, all final decisions regarding study modifica-
tions rest with the Executive Committee. All cumulative
safety data will be reported to the DSMB and reviewed
on an ongoing basis throughout enrollment and follow-
up periods to ensure patient safety. Every effort will be
made to allow the DSMB to conduct an unbiased review
of patient safety information. The DSMB will develop a
consensus understanding of all trial endpoints and defi-
nitions used in the event adjudication process. All
DSMB reports will remain strictly confidential but will
be made available to the regulatory body upon request.
Critical Events Committee
The Critical Events Committee (CEC) consists of two
experienced clinical cardiologist who will not participate
van der Schaaf et al. Trials 2010, 11:89
http://www.trialsjournal.com/content/11/1/89
Page 7 of 9in the trial. The CEC will adjudicate all major adverse
cardiac events in this trial as specified by the study pro-
tocol. Both members of the CEC will be blinded to the
primary results of the trial.
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